Original articleDistinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis
Section snippets
Patients
Patients with DM (age >18 years) were seen in the outpatient clinics at the Stanford University Department of Dermatology between July 2004 and April 2013. Patients were followed up for multiple visits (on average every 3-6 months) with a median time of follow-up of 361 days. The Stanford Institutional Review Board approved the collection of plasma and clinical information. Patients were considered to have DM if they met “probable” or “definite” criteria for DM based on Bohan and Peter11, 12
Patient characteristics and autoantibody frequencies
Major demographic and systemic features of the cohort are shown in Table I. The cohort was mostly (72%) female with a median age of 48.4 years (range 4.6-86.9 years) at age of diagnosis and had an average of 5.3 ± 5.1 years of follow-up. A total of 28 (21%) patients were clinically amyopathic, 22 (16%) had ILD, and 28 (21%) had a cancer-associated DM.
Of 134 patients, 111 (83%) had at least 1 circulating autoantibody against 1 of the tested antigens. Plasma from 12 (9%) patients reacted with 2
Discussion
We have applied a sensitive and specific serologic assay to characterize the frequency and clinical significance of anti-TIF-1γ antibodies in a large US cohort of adult patients with DM. Anti-TIF-1γ was the most common autoantibody in our cohort, seen in 41% of patients. Previously reported frequencies for anti-TIF-1γ in adult DM range from 7% to 24%,6, 8, 10, 18 and our higher prevalence could be a result of the increased sensitivity of our assay and the patient population. It is possible that
References (28)
- et al.
UV radiation regulates Mi-2 through protein translation and stability
J Biol Chem
(2008) - et al.
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study
J Am Acad Dermatol
(2011) Myositis specific autoantibodies
Curr Rheumatol Rep
(2006)- et al.
Autoantibodies in polymyositis and dermatomyositis
Curr Rheumatol Rep
(2013) - et al.
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis
Arthritis Res Ther
(2011) - et al.
A novel autoantibody to a 155-kd protein is associated with dermatomyositis
Arthritis Rheum
(2006) - et al.
Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy
Rheumatology
(2007) - et al.
Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis
Arthritis Rheum
(2012) - et al.
Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-center, cross-sectional study
Scand J Rheumatol
(2009) - et al.
Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis
Rheumatology
(2010)
Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy
Medicine (Baltimore)
Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients
J Dermatol
Polymyositis and dermatomyositis (first of two parts)
N Engl J Med
Polymyositis and dermatomyositis (second of two parts)
N Engl J Med
Cited by (136)
Skin manifestations and autoimmune disturbances in dermatomyositis
2023, Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic DiseasesCancer and myositis: Who, when, and how to screen
2022, Best Practice and Research: Clinical RheumatologyMyofascial edema of gastrocnemius: A prominent MRI characteristic in dermatomyositis patients with anti-transcriptional intermediate factor 1-γ antibody
2024, CNS Neuroscience and Therapeutics
Drs Fiorentino and Rosen are supported by National Institutes of Health (NIH) AR062615-01A1. Dr Rosen is supported by NIH RO1 AR-44684 and the Donald and Dorothy Stabler Foundation. The Johns Hopkins Rheumatic Diseases Research Core Center, where the assays were performed, is supported by NIH P30-AR-053503.
Conflicts of interest: None declared.